Melanotan II

How It Works

The biology, explained.

Your skin contains cells called melanocytes.

These cells produce melanin, the pigment that contributes to skin, hair, and eye coloration.

Melanin also participates in the skin's responses to ultraviolet radiation.

But pigmentation isn't controlled by sunlight alone.

It's also influenced by hormones and receptor signaling.

Meet alpha-MSH

Alpha-MSH stands for alpha-melanocyte-stimulating hormone.

It's part of a larger family of signaling peptides derived from a precursor called proopiomelanocortin, or POMC.

Alpha-MSH interacts with melanocortin receptors.

There are several melanocortin receptor subtypes, each involved in different biological functions.

That helps explain why melanocortin peptides can produce effects in multiple organ systems.

The pigmentation receptor: MC1R

MC1R is especially important in melanocytes.

When activated, it can increase signaling that promotes eumelanin production.

Eumelanin is a brown-to-black pigment.

A simplified version of the pathway looks like this:

Melanocortin signal → MC1R activation → intracellular cAMP signaling → increased melanogenic activity → more pigment production.

The actual biology includes additional regulators and feedback mechanisms.

Genetic variation in MC1R also helps explain why people differ in natural pigmentation and tanning responses.

Where does Melanotan II come in?

Melanotan II is a synthetic analog of alpha-MSH.

Researchers designed it to activate melanocortin receptors with strong biological activity.

Unlike a receptor-selective pigment drug, Melanotan II interacts with multiple melanocortin receptor subtypes.

That explains why its effects can extend beyond skin pigmentation.

Why is it cyclic?

Melanotan II contains seven amino-acid residues.

Its structure includes a lactam ring connecting two amino-acid side chains.

That constrained molecular architecture changes its shape and influences receptor binding.

The molecule also contains nonstandard structural features, including norleucine and D-phenylalanine.

These modifications distinguish it from naturally occurring alpha-MSH.

The sexual-response discovery

Some melanocortin receptors are found in the nervous system.

MC4R, in particular, participates in several centrally regulated functions.

Researchers studying Melanotan II observed stretching, yawning, and spontaneous erections in human volunteers.

Subsequent clinical experiments explored erectile responses in men with different forms of erectile dysfunction.

This research helped establish melanocortin signaling as a potential target in sexual medicine.

But Melanotan II and PT-141 are different molecules.

And PT-141's FDA approval does not apply to Melanotan II.

The appetite connection

Central melanocortin pathways also contribute to energy balance and food-intake regulation.

MC4R is important in the brain's control of appetite.

Some people using Melanotan II describe decreased appetite.

Early clinical studies also recorded appetite-related effects.

But that doesn't establish Melanotan II as a safe or effective weight-loss treatment.

Does it create a sunless tan?

The phrase "sunless tanning peptide" is misleading.

Melanotan II can promote melanogenic activity, and early studies observed pigmentation changes under controlled conditions.

But the response varies and may be influenced by ultraviolet exposure and individual biology.

More importantly, a darker skin tone does not establish protection against UV-induced DNA damage.

A tan isn't sunscreen.

Why can freckles and moles darken?

Freckles and melanocytic lesions involve cells and pigment systems responsive to melanocortin signaling.

Melanotan II exposure can produce rapid darkening of existing pigmented areas and changes in the appearance of skin lesions.

That matters because new or changing lesions may require medical evaluation.

It also makes the skin-cancer safety question much more complicated.

Go deeper: The science

Melanotan II is a cyclic heptapeptide with the structure:

Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-NH₂.

Its lactam ring forms between the side chains of Asp and Lys.

It is a nonselective melanocortin receptor agonist, with clinically relevant research involving MC1R and central melanocortin pathways.

Pigmentation signaling includes melanocyte cAMP pathways, while central receptor activation is relevant to appetite and sexual response.

The precise relationship between long-term melanocortin receptor stimulation, changes in melanocytic lesions, and melanoma biology remains unresolved.

The Evidence

What do the studies actually show?

Melanotan II has genuine human research.

Its early studies are particularly interesting because they show both the intended pigmentation effects and unexpected systemic effects.

But the trials were generally small.

Modern concerns largely arise from case reports, pharmacological reasoning, and testing of unregulated products.

1996: The three-person pilot experiment

Researchers enrolled three healthy male volunteers in a single-blind, alternating placebo-controlled pilot study.

They investigated subcutaneous Melanotan II and measured pigmentation and adverse effects.

Two of the three participants developed increased pigmentation in several body regions.

Researchers also documented:

• Nausea.
• Somnolence or fatigue at higher experimental exposures.
• Stretching and yawning.
• Spontaneous erections.

Some erectile responses lasted intermittently during observation periods extending several hours.

The study established a notable biological signal.

But three people cannot establish long-term safety or a reliable population-level benefit.

1998: The erectile-response trial

Researchers enrolled 10 men with psychogenic erectile dysfunction in a double-blind, placebo-controlled crossover study.

They measured penile rigidity objectively.

The difference in rigidity duration was statistically significant.

Researchers also reported more nausea, stretching, yawning, and decreased appetite.

This was evidence that Melanotan II could influence erectile physiology under experimental conditions.

It did not establish an approved erectile-dysfunction therapy.

2000: A second controlled trial

Another double-blind crossover study enrolled 10 men with organic erectile dysfunction.

Researchers examined subjective erectile responses, rigidity, desire, and adverse effects.

Across the evaluable administrations:

The study also found increased reported sexual desire.

But nausea was prominent.

Four of the 19 Melanotan II administrations were associated with severe nausea.

That's an unusually important piece of evidence because it connects the biological signal with a substantial tolerability problem.

Why did PT-141 emerge from this field?

Melanocortin researchers were interested in separating desirable effects from unwanted ones.

The development of PT-141 followed a related research direction involving sexual response.

PT-141 eventually became the FDA-approved drug bremelanotide, marketed as Vyleesi, for a specific form of low sexual desire in premenopausal women.

Melanotan II itself never received equivalent FDA approval.

What about melanoma?

This is the most complicated—and most important—part of the research.

There are published reports of melanoma diagnoses after Melanotan II exposure.

There are also reports of rapidly darkening or eruptive pigmented lesions.

But these observations require careful interpretation.

A case report can show that a concerning event occurred after an exposure.

It generally cannot establish that the exposure caused the event.

Some affected patients also had UV exposure, tanning-bed use, genetic predisposition, or other risk factors.

The 2025 oral melanoma report

A case report published in 2025 described a 22-year-old woman who developed a lesion in the anterior maxilla after using a Melanotan II nasal spray.

The authors raised the possibility of a relationship with oral mucosal malignant melanoma.

But the report does not establish causation.

A single case cannot measure the risk of developing melanoma after exposure.

The remarkable 2026 case

A 2026 report described a 49-year-old man who presented with multiple atypical pigmented lesions.

He reported recent exposure to:

• Melanotan II.
• Melanotan I.
• Tanning beds.
• Anabolic hormones.

He noticed rapid darkening of preexisting nevi.

Subsequent investigation identified five primary melanomas in situ.

That is a serious clinical observation.

But the multiple simultaneous exposures make it impossible to attribute the findings to Melanotan II specifically.

It is evidence of a concerning association requiring further investigation—not proof that Melanotan II directly caused five melanomas.

The 2024 scientific review

A review of chronic MC1R activation examined the potential benefits and risks of melanocortin-related approaches.

The authors discussed melanoma case reports following Melanotan II use, alongside ultraviolet exposure and genetic risk factors.

The review emphasized the limitations of nonlicensed substances and the importance of skin examinations.

Importantly, MC1R signaling itself is biologically complex.

It cannot simply be categorized as universally cancer-protective or cancer-promoting.

A real 2026 product-quality investigation

The Australian Therapeutic Goods Administration investigated unapproved Melanotan II nasal sprays.

Laboratory testing confirmed Melanotan II in five bottles labeled as containing 30 mg.

But estimated total content ranged from approximately 22 mg to 54 mg per bottle.

That's an enormous variation for nominally identical products.

This finding shows why a research-market label cannot be treated as reliable proof of dose or consistency.

Does it prevent skin cancer?

No.

There is no convincing clinical evidence establishing Melanotan II as a safe method to prevent skin cancer.

Pigmentation is not equivalent to protection against UV-induced damage.

Using tanning beds or intentionally increasing UV exposure can independently increase skin-cancer risk.

What about appetite suppression?

Some clinical participants reported decreased appetite, and melanocortin pathways are biologically relevant to energy regulation.

But there are no adequate modern clinical trials demonstrating that Melanotan II is an appropriate treatment for obesity.

The takeaway

Melanotan II can influence pigmentation and sexual responses in humans.

Those effects were observed in actual clinical experiments.

But the research does not establish safe cosmetic tanning, long-term safety, melanoma prevention, or an approved treatment for erectile dysfunction or weight management.

Its discovery illustrates both the promise and danger of activating a signaling system that operates throughout the body.

Risks & Effects

What should people know?

Melanotan II's safety story is unusually important because unapproved products are widely marketed for cosmetic purposes.

Common effects observed in early human research

Small clinical studies documented:

• Nausea.
• Stretching and yawning.
• Fatigue or sleepiness.
• Spontaneous erections.
• Decreased appetite.

These aren't merely internet anecdotes.

They were observed in controlled human research.

Skin changes

Users and clinicians have reported:

• Darkening freckles.
• Darkening existing moles.
• Newly noticeable pigmented lesions.
• Uneven skin pigmentation.
• Darkening of facial or mucosal regions.

A changing lesion shouldn't automatically be dismissed as an expected tanning response.

Clinically suspicious pigmented changes warrant dermatologic assessment.

Does it cause melanoma?

The evidence doesn't establish a causal melanoma risk or quantify its size.

But there are published melanoma case reports after exposure, and skin-cancer organizations have warned about the potential danger of these products.

It would be just as inaccurate to declare the compound a proven cause of melanoma as to claim that it's cancer-safe.

The unanswered question is clinically significant.

Prolonged erections and priapism

Melanotan II has documented erectile effects.

Rare case reports describe ischemic priapism after unapproved Melanotan II use.

In one 2021 report, a patient presented after an erection persisted approximately 30 hours.

The event required surgical treatment after initial measures failed.

An erection lasting four hours or more is an emergency because prolonged ischemia can cause permanent tissue damage.

Kidney-related reports

A 2020 case report described renal infarction considered possibly related to Melanotan II exposure.

The investigators identified the peptide in a supplied product sample.

The case does not establish that kidney infarction is a common or predictable effect, but it is a significant safety signal.

Other medical reports have described serious complications involving kidney dysfunction or muscle injury.

Nasal-spray problems

A commercial nasal product can vary in:

• Chemical identity.
• Concentration.
• Container quality.
• Delivered volume.
• Preservatives and excipients.
• Stability and microbiological quality.

The 2026 Australian testing showing 22–54 mg in products labeled 30 mg provides direct evidence of inconsistent formulation.

A nasal spray is not necessarily safer just because it avoids an injection.

Injectable-product problems

Unregulated injectable peptides create additional risks involving sterility, contamination, and dosing accuracy.

There is no validated universal formulation or safety protocol for products sold as Melanotan II through research websites.

Does a darker tan reduce sun damage?

Not reliably.

A tan is a sign of increased pigmentation, and UV-induced tanning can accompany DNA damage.

A darker appearance is not equivalent to sunscreen.

UV avoidance, protective clothing, and appropriately applied broad-spectrum sunscreen remain important.

Regulatory status

Melanotan II is not FDA-approved for any use.

The FDA has previously taken enforcement action against unapproved Melanotan II products marketed with tanning and skin-cancer-prevention claims.

Australian regulators have also warned against unapproved Melanotan products and documented problems with product quality.

Its research history does not establish that commercial tanning preparations are safe.

Bottom line

Melanotan II has genuine biological effects.

But its unapproved formulations, pigmentation changes, severe adverse-event reports, and unresolved skin-cancer questions make cosmetic self-use particularly concerning.

Real Experiences

What are people saying?

Melanotan II has a large online following.

And the firsthand stories reveal a fascinating conflict.

Some people love the rapid pigmentation changes.

Others stop precisely because of those same changes.

The good: A dramatic change in skin tone

Some people with naturally light skin describe gaining pigment more readily than they normally would.

One June 2026 account described developing noticeable color after about a week, alongside temporary flushing and nausea.

Others describe substantial darkening over a couple of weeks.

These experiences are consistent with the peptide's known melanogenic activity, but they don't prove a particular product is safe or that it prevents sunburn.

The unexpected: Libido changes before tanning

Some users describe increased sexual desire or spontaneous erections before noticeable pigment changes.

That pattern is interesting because early clinical trials also documented sexual responses.

But subjective experiences remain highly variable.

The frustrating: Freckles darken first

This is one of the most recognizable themes in community discussions.

Users frequently describe freckles, moles, or isolated pigmented spots darkening more quickly than surrounding skin.

One November 2025 account described stopping after several days because the freckles on the user's face and chest became dramatically darker.

Some people enjoy the added freckles.

Others find the uneven appearance distressing.

The not-so-good: Nausea

Some people report only mild nausea.

Others describe intense stomach discomfort, flushing, fatigue, or an unpleasant general feeling.

One October 2026 discussion compared Melanotan I and II, with several participants describing greater nausea and more intense pigmentation effects from Melanotan II.

These are personal impressions, not controlled comparative safety data.

The surprise: Appetite suppression

Some users describe being less hungry.

Others notice no appetite change.

That variability is consistent with why researchers remain interested in central melanocortin signaling, but it doesn't establish an effective weight-management treatment.

The disappointment: Minimal tanning

Not everyone achieves the appearance they expected.

One June 2026 account described new freckles and sexual effects without much of the desired overall tanning.

People may also vary in UV exposure, genetics, product identity, and other factors.

Those differences make individual results difficult to interpret.

The concerning: New or changing moles

Some people post photographs of newly darkened or changing pigmented lesions and ask whether the changes are normal.

That's not something an online community can reliably diagnose.

A changing or suspicious mole should be examined by an appropriate clinician.

The important limitation

Many reports also involve deliberate sun exposure or tanning beds.

That creates a major confounding variable.

The appearance of a darker tan cannot reliably tell us how much pigmentation came from Melanotan II versus UV exposure.

And neither appearance nor subjective experience establishes long-term skin safety.

So what should we believe?

The community experiences illustrate that Melanotan II can produce striking and unpredictable cosmetic effects.

They also show why people may seek it out—and why some stop.

But they cannot establish the risk of melanoma, the safety of underground products, or a predictable response for an individual person.

The most important scientific question isn't simply whether Melanotan II can darken skin. We already have human evidence that it can. The question is whether that biology can be harnessed safely.

These summaries reflect real public discussions. Individual reports are unverified and do not establish causation, treatment effectiveness, or reliable adverse-event rates.